On January 8, 2025 Taiho Oncology, Inc. reported presentations at the 2025 ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO GI), to be held Jan. 23-25, 2025, in San Francisco (Press release, Taiho, JAN 8, 2025, View Source [SID1234649519]). The poster presentations include a comparison of real-world clinical outcomes of patients with metastatic colorectal cancer (mCRC) who received trifluridine and tipiracil (FTD/TPI) monotherapy or FTD/TPI + bevacizumab (FTD/TPI+bev) combination therapy and an additional analysis of the same dataset on real-world clinical outcomes in 639 black patients with mCRC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Access to real-world clinical outcomes of FTD/TPI monotherapy versus FTD/TPI+bev combination therapy among patients with mCRC, could provide valuable insights to ultimately help improve clinical development and treatment protocols, broadly and in underrepresented populations," said Tehseen Salimi, MD, MHA, Senior Vice President and Head of Medical Affairs, Taiho Oncology. "At Taiho Oncology, our understanding of patient experience is a driving force that allows us to bring innovative cancer therapies to patients."

Details for both studies and data to be presented can be found below:

Title: Real-World Clinical Outcomes of Patients (Pts) with Metastatic Colorectal Cancer (mCRC) Who Received Trifluridine-Tipiracil (FTD-TPI) Monotherapy or FTD-TPI + Bevacizumab (FTD-TPI+bev) Combination Therapy
Abstract Number: 79
Session Name: Poster Session C: Cancers of the Colon, Rectum, and Anus
Session Date: Jan. 25, 2025
Session Time: 7 – 7:55 a.m. PST
Location: Level 1, West Hall | On Demand
Presenter: Maliha Nusrat, MD, MS

Title: Real-World Clinical Outcomes of Trifluridine-Tipiracil Monotherapy (FTD-TPI) and FTD-TPI + Bevacizumab Combination Therapy (FTD-TPI+bev) in 639 Black patients (pts) with Metastatic Colorectal Cancer (mCRC)
Abstract Number: 81
Session Name: Poster Session C: Cancers of the Colon, Rectum, and Anus
Session Date: Jan. 25, 2025
Session Time: 7 – 7:55 a.m. PST
Location: Level 1, West Hall | On Demand
Presenter: Maliha Nusrat, MD, MS